
Intra-Cellular Therapies Inc
NASDAQ:ITCI

Intra-Cellular Therapies Inc?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
64.76
131.92
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Intra-Cellular Therapies Inc hold over its rivals?
What risks and challenges
does Intra-Cellular Therapies Inc face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Intra-Cellular Therapies Inc.
Provide an overview of the primary business activities
of Intra-Cellular Therapies Inc.
What unique competitive advantages
does Intra-Cellular Therapies Inc hold over its rivals?
What risks and challenges
does Intra-Cellular Therapies Inc face in the near future?
Has there been any significant insider trading activity
in Intra-Cellular Therapies Inc recently?
Summarize the latest earnings call
of Intra-Cellular Therapies Inc.
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Intra-Cellular Therapies Inc.
Provide P/S
for Intra-Cellular Therapies Inc.
Provide P/E
for Intra-Cellular Therapies Inc.
Provide P/OCF
for Intra-Cellular Therapies Inc.
Provide P/FCFE
for Intra-Cellular Therapies Inc.
Provide P/B
for Intra-Cellular Therapies Inc.
Provide EV/S
for Intra-Cellular Therapies Inc.
Provide EV/GP
for Intra-Cellular Therapies Inc.
Provide EV/EBITDA
for Intra-Cellular Therapies Inc.
Provide EV/EBIT
for Intra-Cellular Therapies Inc.
Provide EV/OCF
for Intra-Cellular Therapies Inc.
Provide EV/FCFF
for Intra-Cellular Therapies Inc.
Provide EV/IC
for Intra-Cellular Therapies Inc.
Show me price targets
for Intra-Cellular Therapies Inc made by professional analysts.
What are the Revenue projections
for Intra-Cellular Therapies Inc?
How accurate were the past Revenue estimates
for Intra-Cellular Therapies Inc?
What are the Net Income projections
for Intra-Cellular Therapies Inc?
How accurate were the past Net Income estimates
for Intra-Cellular Therapies Inc?
What are the EPS projections
for Intra-Cellular Therapies Inc?
How accurate were the past EPS estimates
for Intra-Cellular Therapies Inc?
What are the EBIT projections
for Intra-Cellular Therapies Inc?
How accurate were the past EBIT estimates
for Intra-Cellular Therapies Inc?
Compare the revenue forecasts
for Intra-Cellular Therapies Inc with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Intra-Cellular Therapies Inc and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Intra-Cellular Therapies Inc against its competitors.
Analyze the profit margins
(gross, operating, and net) of Intra-Cellular Therapies Inc compared to its peers.
Compare the P/E ratios
of Intra-Cellular Therapies Inc against its peers.
Discuss the investment returns and shareholder value creation
comparing Intra-Cellular Therapies Inc with its peers.
Analyze the financial leverage
of Intra-Cellular Therapies Inc compared to its main competitors.
Show all profitability ratios
for Intra-Cellular Therapies Inc.
Provide ROE
for Intra-Cellular Therapies Inc.
Provide ROA
for Intra-Cellular Therapies Inc.
Provide ROIC
for Intra-Cellular Therapies Inc.
Provide ROCE
for Intra-Cellular Therapies Inc.
Provide Gross Margin
for Intra-Cellular Therapies Inc.
Provide Operating Margin
for Intra-Cellular Therapies Inc.
Provide Net Margin
for Intra-Cellular Therapies Inc.
Provide FCF Margin
for Intra-Cellular Therapies Inc.
Show all solvency ratios
for Intra-Cellular Therapies Inc.
Provide D/E Ratio
for Intra-Cellular Therapies Inc.
Provide D/A Ratio
for Intra-Cellular Therapies Inc.
Provide Interest Coverage Ratio
for Intra-Cellular Therapies Inc.
Provide Altman Z-Score Ratio
for Intra-Cellular Therapies Inc.
Provide Quick Ratio
for Intra-Cellular Therapies Inc.
Provide Current Ratio
for Intra-Cellular Therapies Inc.
Provide Cash Ratio
for Intra-Cellular Therapies Inc.
What is the historical Revenue growth
over the last 5 years for Intra-Cellular Therapies Inc?
What is the historical Net Income growth
over the last 5 years for Intra-Cellular Therapies Inc?
What is the current Free Cash Flow
of Intra-Cellular Therapies Inc?
Discuss the annual earnings per share (EPS)
trend over the past five years for Intra-Cellular Therapies Inc.
P/E
Price to Earnings
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
Market Cap | P/E | ||||
---|---|---|---|---|---|
US |
![]() |
Intra-Cellular Therapies Inc
NASDAQ:ITCI
|
14B USD | -187.6 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
694B USD | 65.5 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | -15 783.5 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
365.2B USD | 26 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK | 18.5 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
194.4B CHF | 16.9 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
174.3B CHF | 17.9 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
155.2B GBP | 28.9 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
200.5B USD | 11.7 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD | -55.5 |
|
FR |
![]() |
Sanofi SA
PAR:SAN
|
111.8B EUR | 19.5 |
|
Earnings Growth | PEG | |||||
---|---|---|---|---|---|---|
US |
![]() |
Intra-Cellular Therapies Inc
NASDAQ:ITCI
|
Average P/E:
25.6
|
N/A | N/A | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
65.5
|
49%
|
1.3 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
Negative Multiple: -15 783.5 | N/A | N/A |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
26
|
26%
|
1 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
18.5
|
19%
|
1 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
16.9
|
16%
|
1.1 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
17.9
|
16%
|
1.1 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
28.9
|
36%
|
0.8 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
11.7
|
18%
|
0.7 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
Negative Multiple: -55.5 | N/A | N/A |
|
FR |
![]() |
Sanofi SA
PAR:SAN
|
19.5
|
28%
|
0.7 |
|
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.